Unsere Publikationen

Long-term real-world evidence for sustained clinical benefits of fingolimod following switch from natalizumab

Link
https://doi.org/10.1016/j.msard.2019.101893
Tags
Multiple SkleroseMS Behandlung
Jahr
2020
Autoren
Ziemssen T, Lang M, Tackenberg B, Schmidt S, Albrecht H, Klotz L, Haas J, Lassek C, Cornelissen C, Ettle B; PANGAEA Study Group.
Verlag
Mult Scler Relat Disord. 2020 Apr;39:101893.
Zum Eintrag

Letter to the editor regarding “Therapeutic drug monitoring of natalizumab”

Link
https://doi.org/10.1177/1352458519837702
Tags
Multiple SkleroseMS Behandlung
Jahr
2020
Autoren
Proschmann U, Sehr T, Akgün K, Ziemssen T.
Verlag
Mult Scler J 2020;26(6):741-742.
Zum Eintrag

Fingolimod Leads to Immediate Immunological Changes Within 6 h After First Administration

Link
https://doi.org/10.3389/fneur.2020.00391
Tags
Multiple SkleroseMS Behandlung
Jahr
2020
Autoren
Sehr T, Akgün K, Haase R, Ziemssen T.
Verlag
Front Neurol 2020;11.
Zum Eintrag

Gaining first insights on secondary progressive multiple sclerosis patients treated with siponimod in clinical routine: Protocol of the noninterventional study Amasia

Link
https://doi.org/10.2196/19598
Tags
Multiple SkleroseMS Behandlung
Jahr
2020
Autoren
Ziemssen T, Hoffmann O, Klotz L, Schreiber H, Weber MS, Rauser B.
Verlag
JMIR Res Prot 2020;9(7).
Zum Eintrag

A Comprehensive Monitoring Study on Electrocardiographic Assessments and Cardiac Events After Fingolimod First Dose—Possible Predictors of Cardiac Outcomes

Link
https://doi.org/10.3389/fneur.2020.00818
Tags
Multiple SkleroseMS Behandlung
Jahr
2020
Autoren
Limmroth V, Ziemssen T, Kleiter I, Wagner B, Schmidt S, Lassek C, Baier-Ebert M, Wendt G, Dechend R, Haverkamp W.
Verlag
Front Neurol. 2020 Aug 12;11:818.
Zum Eintrag

Efficacy and Safety of Alemtuzumab Through 9 Years of Follow-up in Patients with Highly Active Disease: Post Hoc Analysis of CARE-MS I and II Patients in the TOPAZ Extension Study

Link
https://doi.org/10.1007/s40263-020-00749-x
Tags
Multiple SkleroseMS Behandlung
Jahr
2020
Autoren
Ziemssen T, Bass AD, Berkovich R, Comi G, Eichau S, Hobart J, Hunter SF, LaGanke C, Limmroth V, Pelletier D, Pozzilli C, Schippling S, Sousa L, Traboulsee A, Uitdehaag BMJ, Van Wijmeersch B, Choudhry Z, Daizadeh N, Singer BA; CARE-MS I, CARE-MS II, CAMMS03409, and TOPAZ investigators.
Verlag
CNS Drugs. 2020 Sep;34(9):973-988.
Zum Eintrag

No Impact of Long-Term Fingolimod Treatment on Fecal Secretory Immunoglobulin A Levels in Patients With Multiple Sclerosis

Link
https://doi.org/10.3389/fcell.2020.567659
Tags
Multiple SkleroseMS Behandlung
Jahr
2020
Autoren
Inojosa H, Eisele J, Proschmann U, Zeissig S, Akgün K, Ziemssen T.
Verlag
Front Cell Dev Biol 2020;8.
Zum Eintrag

Diroximel fumarate (DRF) in patients with relapsing–remitting multiple sclerosis: Interim safety and efficacy results from the phase 3 EVOLVE-MS-1 study

Link
https://doi.org/10.1177/1352458519881761
Tags
Multiple SkleroseMS Behandlung
Jahr
2020
Autoren
Naismith RT, Wolinsky JS, Wundes A, LaGanke C, Arnold DL, Obradovic D, Freedman MS, Gudesblatt M, Ziemssen T, Kandinov B, Bidollari I, Lopez-Bresnahan M, Nangia N, Rezendes D, Yang L, Chen H, Liu S, Hanna J, Miller C, Leigh-Pemberton R.
Verlag
Mult Scler. 2020 Nov;26(13):1729-1739.
Zum Eintrag

Publikationen durchsuchen

Publikationen filtern

Filter
Tags
Multiple Sklerose
MS Behandlung
Mobilität
Autonomes Nervensystem & Neuroendokrinologie
Neuroimmunologie
Herzratenvariabilität
Baroreflexsensitivität
Management & Science
eHealth
Gesundheitsökonomie
Andere
Zeige alleVerstecke
Jahr
-